VECTION TECHNOLOGIES LTD — Capital/Financing Update 2021

Mar 10, 2021

11 March 2021 | Australia

==> picture [130 x 44] intentionally omitted <==

ASX RELEASE

LAUNCH OF HEALTHCARE & PHARMA SOLUTIONS VERTICAL

FIRST MILESTONE IN THE 2021 VERTICALIZATION STRATEGY

Real-time software company Vection Technologies Ltd ( ASX:VR1 ) ( Vection Technologies , Vection or the Company ) is pleased to announce the acceleration of its Verticalization growth strategy with the launch of its Healthcare & Pharma Solutions division.

The Company will be joining forces with a strong team of professionals led by Dr Carlo Centemeri, a leading healthcare and pharma executive with senior experience in BASF, Knoll Pharmaceuticals, Abbott Laboratories, Bristol-Myers Squibb and AstraZeneca. Furthermore, he led as Managing Director the Education and Simulation Center of the Gemelli University Hospital in Rome and Elsevier Pharma & Health Industries as Executive Director. He currently serves as Medical Science Senior Advisor to the Italian Ministry of Health and as Strategy and Development Senior Managing Partner at the Giovanni Lorenzini Medical Foundation of Milan and New York. Carlo is an Adjunct Professor of Pharmacology at Padua, Milan and Rome Universities.

Highlights:

• Vection strongly accelerates its international growth strategy with the launch of its Healthcare & Pharma Solutions Division

• Vection joins forces with highly experienced team with former roles in BASF, Knoll Pharmaceuticals, Abbott Laboratories, Bristol-Myers Squibb, AstraZeneca, Novartis, Boehringer Ingelheim and Dompé Farmaceutici

• Strong commitment by the executive team with joint division ownership and strong opportunities pipeline anticipated to come to fruition from April 2021

==> picture [25 x 25] intentionally omitted <==

3D VIRTUAL REALITY

==> picture [25 x 25] intentionally omitted <==

AUGMENTED REALITY INDUSTRIAL IoT CAD

• acceleration

• Expansion of Vection’s footprint in the healthcare, pharmaceutical, biotechnological, medical devices and nutraceutical market segments leveraging its existing core technology stack

• Strategic division for continued growth during the current pandemic aligned with the digital transformation trend in healthcare

• First milestone in the 2021 Verticalization strategy achieved

• A brief presentation of the Healthcare & Pharma Solutions division is appended to this announcement

Vection Technologies Ltd (ASX:VR1) ACN: 614 814 041

Address: 642 Newcastle Street, Leederville WA 6007

Media Enquiries AUpress@vection.com.au EUpress@vection.com.au

==> picture [23 x 35] intentionally omitted <==

1

Europe North America Address: Via Isonzo 61 Address: 785 Market Street, #600 40033 Casalecchio di Reno (BO), San Francisco CA 94103 Italy USA

Phone: +618 6380 2555

==> picture [130 x 44] intentionally omitted <==

Vection Healthcare & Pharma Solutions - Overview :

Centemeri to lay the necessary groundwork to achieve the optimum global market penetration for the second half growth. Today, following extensive negotiations, the Company has secured the strong commitment of Dr Centemeri through the incorporation of a joint venture company controlled by Vection at 60%. ( Vection Healthcare & Pharma Solutions )

Vection Healthcare & Pharma Solutions - Rationale:

The shareholding structure of Vection Healthcare & Pharma Solutions ensures a strong commitment on global growth by the executive team of this vertical, in addition to delivering a significant pipeline of opportunities anticipated to come to fruition commencing from the month of April 2021.

Vection Healthcare & Pharma Solutions - Executive Team:

Through the incorporation of Vection Healthcare & Pharma Solutions, the Company has secured a team of 6 professionals with previous experience in strategic companies including BASF, Knoll Pharmaceuticals, Abbott Laboratories, Bristol-Myers Squibb, AstraZeneca, Novartis, Boehringer Ingelheim and Dompé Farmaceutici.

Vection Healthcare & Pharma Solutions - Strategy :

Vection Healthcare & Pharma Solutions represents a strong acceleration in the Company’s Verticalization strategy, a tactical approach that seeks to significantly expand Vection’s footprint in the healthcare, pharmaceutical, biotechnological, medical devices and nutraceutical market segments.

education & communication by becoming the reference solution provider for the public and private sector operating in the life-science world. It will develop unique and highly innovative educational and communication models in the the healthcare, pharmaceutical, biotechnological, medical devices, and nutraceutical market segments through the vertical integration of Vection’s current core technology stack.

==> picture [25 x 25] intentionally omitted <==

3D VIRTUAL REALITY

==> picture [25 x 25] intentionally omitted <==

AUGMENTED REALITY INDUSTRIAL IoT CAD

The proposed training and communication approach adopts, among others, advanced behavioural simulation techniques including Virtual and Augmented Reality technologies, that have demonstrated essential benefits across diverse market segments for increased quality of teaching and learning, to ensure the effective education of Health Care Professionals ( HCPs ) and personnel.

Leveraging the overarching organizational, structural and methodological renewal trend of the entire healthcare industry, Vection Healthcare & Pharma Solutions seeks to take advantage of all the opportunities that digital education offers. Thus, the development of medical practices, the improvement of soft skills relationships with patients and caregivers and the advancement of business acumen between all health stakeholders is today one of the crucial elements of the digital transformation in the health sciences where Vection seeks to operate.

Vection Technologies Ltd (ASX:VR1) ACN: 614 814 041

Europe Address: Via Isonzo 61 40033 Casalecchio di Reno (BO), Italy

North America Address: 785 Market Street, #600 San Francisco CA 94103 USA

Media Enquiries AUpress@vection.com.au EUpress@vection.com.au

==> picture [23 x 35] intentionally omitted <==

2

Address: 642 Newcastle Street, Leederville WA 6007 Phone: +618 6380 2555

==> picture [130 x 44] intentionally omitted <==

A brief presentation of the Healthcare & Pharma Solutions division is appended to this announcement.

Gianmarco Biagi, Managing Director of Vection Technologies, commented:

“ The Healthcare & Pharma Solutions division represents a strong acceleration and the achievement of the first milestone in the Company’s overarching Verticalization growth strategy in a key market segment.

fiscal year, we have now secured the full commitment of Dr Centemeri and his team, leading market experts with unrivalled senior experience and network in this vertical - a strong endorsement of the Company’s ability to attract the best talent key for the Company’s growth.

Verticalization growth strategy in the short-term, ensuring unrivalled acceleration in the industry. ”

Carlo Centemeri, CEO of Vection Healthcare, commented:

“ The global COVID-19 pandemic has forced healthcare systems to radically change their operational structure. In this context, digital transformation is paramount and critical.

Our mission is to rapidly gain market share in healthcare education, communication, digital networking, big data and operational solutions through the proposition of outstanding Innovative Technological Methodologies. Our ambition is to become a market reference point as leaders in the behavioural simulation immersive training field, leveraging Vection’s virtual reality, augmented reality, motion capture, morphing and avatar-based solutions. ”

Vection Technologies Investor Relations Contact Details

Gianmarco Biagi - Managing Director (Europe Based)

Email: gianmarco.biagi@vection.com.au Phone: +39 051 0142248

==> picture [25 x 25] intentionally omitted <==

3D VIRTUAL REALITY

==> picture [25 x 25] intentionally omitted <==

AUGMENTED REALITY INDUSTRIAL IoT CAD

Gianmarco Orgnoni - Director and COO (Australia Based) Email: gianmarco.orgnoni@vection.com.au Phone: +61 8 6380 2555

ENDS

Vection Technologies Ltd (ASX:VR1) ACN: 614 814 041

Europe Address: Via Isonzo 61 40033 Casalecchio di Reno (BO), Italy

Media Enquiries AUpress@vection.com.au EUpress@vection.com.au

==> picture [23 x 35] intentionally omitted <==

3

Address: 642 Newcastle Street, Leederville WA 6007 Phone: +618 6380 2555

North America Address: 785 Market Street, #600 San Francisco CA 94103 USA

==> picture [130 x 44] intentionally omitted <==

About Vection Technologies:

Vection Technologies Ltd (ASX:VR1) is a multinational software company that focuses on real-time technologies for industrial companies’ digital transformation.

Through a combination of our 3D, Virtual Reality, Augmented Reality, Industrial IoT and CAD solutions, Vection Technologies helps companies and organisations to innovate, collaborate and create value.

For more information please visit the Company’s websites:

vection.com.au

mindeskvr.com

About the Leading Strategy:

(2017-2018) and Transforming (2019-2020) – resulting in the development of its solid core technology stack, the Company has now progressed to the Leading Strategy phase (2021-2023), with “Verticalization” being its first foundational step. The Verticalization approach seeks to significantly expand Vection’s footprint in companies’ application landscapes, segmenting industrial markets while capturing new business opportunities, protecting market positions and averting competitive threats. As part of this approach, Vection wants to develop highly verticalized extensions to its core technology stack aimed at anchoring its solutions in clients’ core processes. The Company will follow a Build / Acquire / Partner strategy where, in each vertical industry, it will analyse the benefits of internally building functionality, working with a partner or acquiring companies.

==> picture [25 x 25] intentionally omitted <==

3D

==> picture [25 x 25] intentionally omitted <==

VIRTUAL REALITY

==> picture [25 x 25] intentionally omitted <==

AUGMENTED REALITY

ASX release authorised by the Board of Directors of Vection Technologies Ltd.

==> picture [25 x 25] intentionally omitted <==

INDUSTRIAL IoT

==> picture [25 x 25] intentionally omitted <==

CAD

Vection Technologies Ltd (ASX:VR1) ACN: 614 814 041

Europe Address: Via Isonzo 61 40033 Casalecchio di Reno (BO), Italy

Media Enquiries AUpress@vection.com.au EUpress@vection.com.au

==> picture [23 x 35] intentionally omitted <==

4

Address: 642 Newcastle Street, Leederville WA 6007 Phone: +618 6380 2555

North America Address: 785 Market Street, #600 San Francisco CA 94103 USA

==> picture [145 x 40] intentionally omitted <==

VECTION HEALTH CARE & PHARMA (ASX:VR1) MARCH 11, 2021

VECTION HEALTHCARE & PHARMA

DISCLAIMER

This presentation has been prepared by Vection Technologies Limited (ACN 614 814 041) (Vection Technologies or the Company) and is for information purposes only. It does not constitute financial product or investment advice or a recommendation to acquire Vection Technologies shares and has been prepared without taking into account the objectives, financial situation or needs of individuals. Before making an investment decision, prospective investors should consider the appropriateness of the information having regard to their own objectives, financial situation and needs and seek legal and taxation advice appropriate to their jurisdiction. Vection Technologies is not licensed to provide financial product advice in respect of Vection Technologies shares.

Vection, Vection Technologies, FrameS, Mindesk, and their respective logos, are trademarks or registered trademarks of Vection Technologies, or its subsidiaries. All other registered or unregistered trademarks mentioned in this presentation are the property of their respective owners, and no trademark rights to the same are claimed.

Financial Data - All dollar values are in AUD dollars (AUD or $) unless otherwise presented.

Future performance - Forward looking statements, opinions and estimates provided in this presentation are based on assumptions and contingencies which are subject to change without notice, as are statements about market and industry trends, which are based on interpretations of current market conditions. Forward looking statements including projections, guidance on future earnings and estimates are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance. An investment in Vection Technologies shares is subject to investment and other known and unknown risks, some of which are beyond the control of Vection Technologies. No representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this presentation. To the maximum extent permitted by law, none of Vection Technologies employees, its directors, employees or agents, nor any other person accepts any liability, including, without limitation, any liability arising out of fault or negligence, for any loss arising from the use of the information contained in this presentation. In particular, no representation or warranty, express or implied is given as to the accuracy, completeness or correctness, likelihood of achievement or reasonableness of any forecasts, prospects or returns contained in this Presentation nor is any obligation assumed to update such information. Such forecasts, prospects or returns are by their nature subject to significant uncertainties and contingencies. Before making an investment decision, you should consider, with or without the assistance of a financial adviser, whether an investment is appropriate in light of your particular investment needs, objectives and financial circumstances.

1

VECTION HEALTHCARE & PHARMA

INTRODUCTION

Healthcare

The pandemic is rapidly driving organizational change and prompting health IT leaders to consider future needs and opportunities.

healthtechmagazine.net, Dec20

The pandemic has also brought us to a unique moment where we are learning at scale that data science and digital technology can improve human health in powerful ways. This is digital healthcare’s moment, and there are clear steps the international community can take to meet it. Davos Agenda, Jan21

Pharma

COVID-19 and the digital pharma marketing revolution The global outbreak of COVID-19 has forced businesses to radically change their way of working. Healthcare companies have been in the vanguard of this change, with an enormous rise in the use of telehealth and all forms of digital communication and education. …Once the global emergency ends, this trend will continue…

pharmaforum.com, Jan21

2

THE OPPORTUNITY IS NOW

3

VECTION HEALTHCARE & PHARMA

VISION & MISSION

VISION

To provide effective proven Health Solutions

MISSION

To provide outstanding Health Solutions through Innovation and Technology, gaining a growing market share in the field of health education and operation services and being recognised as a leader in the simulation immersive training field.

4

VECTION HEALTHCARE & PHARMA

Immersive experiential training and educational tools

Education & Training

Communication

(advertising & promotion)

Hospital and out-patient software development & Telemedicine

More

==> picture [32 x 37] intentionally omitted <==

==> picture [44 x 43] intentionally omitted <==

Advanced immersive and highly engaging webinars Coaching/training for sales and medical field forces Strong access to the healthcare sector

Evolved, immersive and engaging platforms for healthcare professionals and public communications Vection’s VR & AR innovative solutions for hospitals and remote-controlled devices and tools Bespoke projects and ad-hoc solutions leveraging a strong industry network

5

STRATEGY for Vection Health & Pharma with greater added value

==> picture [592 x 445] intentionally omitted <==

----- Start of picture text -----

Strong contracts and
orders with clients
Acceleration of commercial
activities
2022
Dec - Jan
Full roll-out of
2021
solutions
Sep - Nov
2021
Projects co-development
May - July
with key clients and opinion
2021
leaders/supporters
----- End of picture text -----

==> picture [68 x 29] intentionally omitted <==

----- Start of picture text -----

April - July
2021
----- End of picture text -----

Intelligence activities with CEO/GMs in the Healthcare & Pharma industry First client sales

6

VECTION HEALTHCARE & PHARMA

PEOPLE

Team with competency and senior experiences in the Pharma and Healthcare field

==> picture [136 x 106] intentionally omitted <==

==> picture [125 x 75] intentionally omitted <==

==> picture [103 x 49] intentionally omitted <==

==> picture [108 x 40] intentionally omitted <==

==> picture [93 x 34] intentionally omitted <==

FLEXIBILITY Flexible team with strong skills and industry specific expertise.

Wealth of experience:

7

VECTION HEALTHCARE & PHARMA

VERTICAL OBJECTIVES

CORE TECHNOLOGIES

MINDESK | FRAMES | TRAINER CREATOR

Healthcare & Pharma	ACE & Real Estate	Comunication & Media	Fashion & Retails	Others
Strong growth segment Internally build functionality Addition of expertise with launch of new division Key Vertical	Strong growth segment External opportunities to expand competencies for value added industry verticalisation Key Vertical	Strong growth segment Internally build functionality Addition of expertise with launch of new division or via external Key Vertical	Strong growth segment Internally build functionality Addition of expertise with launch of new division Key Vertical	dentifcation of technologies key for vertically integrated solutions Including: cyber security, IoT, CAD, BIM and more Identifcation of consulting arm for Key Vertical
		opportunities		value added creation

8

Corporate Headquarters

642 Newcastle Street, Leederville WA 6007

Europe Headquarters

==> picture [268 x 78] intentionally omitted <==

Investor Relations Contact Details

Gianmarco Biagi - Managing Director (Europe Based) Email: gianmarco.biagi@vection.com.au Phone: +39 051 0142248

Gianmarco Orgnoni - Director and COO (Australia Based) Email: gianmarco.orgnoni@vection.com.au Phone: +61 8 6380 2555

Via Isonzo 61, 40033 Casalecchio di Reno (BO), Italy

Europe R&D

Via Volga c/o Fiera del levante, 70132 Bari (BA), Italy

North America Headquarters

785 Market Street, #600 San Francisco CA 94103, USA

India Operations

903, Samedh Complex, Panchvati Cross Road, C.G Road, Ahmedabad – 380009 Gujarat, India

vection.com.au

mindeskvr.com

==> picture [22 x 22] intentionally omitted <==

==> picture [23 x 22] intentionally omitted <==

==> picture [23 x 22] intentionally omitted <==

==> picture [23 x 22] intentionally omitted <==